{"id":"W2343016312","doi":"10.22374/cjgim.v8i0.103","title":"Managing the Patient Being Treated with Biologic Agents for Rheumatic Disease: Pearls for the General Internist","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of General Internal Medicine","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Leflunomide; Sulfasalazine; Hydroxychloroquine; Rheumatoid arthritis; Ankylosing spondylitis; Methotrexate; Psoriatic arthritis; Antirheumatic drugs; Disease; Infliximab; Adalimumab; Tofacitinib; Inflammatory bowel disease; Antirheumatic Agents; Biologic Agents; Arthritis; Tumor necrosis factor alpha; Apremilast; Internal medicine; Ulcerative colitis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002106306,0.0008796083,0.00109337,0.0009506444,0.00204066,0.002383711,0.001308573,0.006852832,0.01228135],"category_scores_gemma":[0.007859711,0.0003617216,0.0007533169,0.0004977432,0.00104102,0.003627978,0.002795601,0.01187297,0.00708944],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001477822,"about_ca_system_score_gemma":0.002596169,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002585949,"about_ca_topic_score_gemma":0.01031335,"domain_scores_codex":[0.9988049,0.0003769752,0.0001288191,0.00007655385,0.0005007506,0.0001119708],"domain_scores_gemma":[0.9953491,0.0009872759,0.0002681027,0.0001157979,0.001142288,0.002137347],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00004992284,0.0002224092,0.001667046,0.0004056119,0.0000294422,0.004786636,0.0006954333,0.0001392493,0.0003222506,0.000847132,0.8623427,0.1284921],"study_design_scores_gemma":[0.0001419017,0.0004789037,0.008283488,0.004889364,0.00007790277,0.04127889,0.004095861,0.0003922764,0.0001242961,0.009230944,0.9308781,0.0001280525],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"other","genre_scores_codex":[0.004368332,0.05047935,0.004611833,0.863883,0.03083299,0.0002718101,0.0001292153,0.0006334392,0.04478999],"genre_scores_gemma":[0.03535305,0.1515545,0.03166205,0.64072,0.08133883,0.0004848433,0.0003617253,0.0002378998,0.05828707],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.01228135,"threshold_uncertainty_score":0.04108524,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02410058734912834,"score_gpt":0.280895509260864,"score_spread":0.2567949219117357,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}